Case Report: HCV-triggered porphyria cutanea tarda in a patient with SEC23B-mutated congenital dyserythropoietic anemia type II

• by Xianghong Jin, Yixuan Li, Yaping Liu, Xianyong Jiang, Junling Zhuang, Min Shen, Miao Chen

• July 13, 2026

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

• by Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry D. Anderson, Rahul Banerjee, Jesus G. Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E. Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C. Pasquini, Othman S. Akhtar, Surbhi Sidana, Krina K. Patel

• August 31, 2026

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

• August 31, 2026

• 5 min

Evidence of nosocomial human-to-human transmission of Dabie bandavirus: a clinical, epidemiological, and virological investigation

• by Shan Hong, Kai Li, Jingqi Yang, Xianfang Peng, Tianshu Cao, Yufei Xie, Yongqiang Deng, Mengxu Sun, Qi Chen, Xiang Chen, Aiping Wu, Hangyu Zhou, Shengjun Wu, Xingyao Huang, Chengfeng Qin

• August 31, 2026